Medical students who report greater knowledge about psilocybin, less concern about its adverse effects, and more support for recreational legalization tend to hold more positive views about its medical use. A survey of 213 U.S. medical students found that these three factors together predicted favorable attitudes toward therapeutic psilocybin, with the model accounting for 57% of the variance. Notably, endorsing recreational legalization was linked to more positive medical-use attitudes, a somewhat counterintuitive result. The study highlights the need for better medical education on psilocybin as its therapeutic potential gains attention.
Among 161 pharmacy students at a southern U.S. school, 75% believed psilocybin should be decriminalized for therapeutic use, but only 34% supported recreational decriminalization. A regression model explained 57% of the variance in students' attitudes: more self-assessed knowledge, less concern about negative effects, and stronger support for both therapeutic and recreational decriminalization predicted more positive views on medical psilocybin. The average age was 24; 12% had used psilocybin recreationally and 1% therapeutically. Students reported minimal training on psilocybin and a desire to learn more, suggesting that attitudes may be shaped by knowledge gaps, safety concerns, and legalization opinions.
Current literature most strongly supports MDMA and intravenous ketamine as treatments for PTSD. Under professional supervision, these agents may reduce PTSD symptoms and are generally well tolerated. However, findings require cautious interpretation because of limitations including treatment expectancy effects and potential inadequate blinding. Additional randomized controlled trials of other psychedelics, such as psilocybin and lysergic acid diethylamide, are necessary to evaluate their effectiveness for PTSD.